Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination

Athanasios Papadas, MD, Evan Flietner, BS, Zachary Morrow, BS, Joshua Wiesner, Alexander Cicala, Adam Pagenkopf, BS, Chelsea L. Hope, PhD, Adhithi Rajagopalan, BS, Zhi Wen, PhD, Philip Emmerich, Dustin Deming, Shigeki Miyamoto, PhD, Peiman Hematti, MD, Natalie Scott Callander, MD, Alexander Rakhmilevich, Mario Otto, MD PhD, Christian M. Capitini, MD, Jing Zhang, PhD, Fotis Asimakopoulos, PhDMBBChir,

Blood (2019) 134 (Supplement_1): 1210.

https://doi.org/10.1182/blood-2019-131582

Published: 2019

Journal Articles

Versican (VCAN) Proteolysis Predicts T-Cell Infiltration in Myeloma Bone Marrow Post- Autologous Stem Cell Transplant (ASCT)

Adam Pagenkopf, Binod Dhakal, MBBS, Chelsea L. Hope, PhD, Athanasios Papadas, MD, Michael G Johnson, PhD, Bradley Nagel, Elena Kurudza, Samik Partha, Bianca Ruffolo, Catherine Leith, MBBChir, Shigeki Miyamoto, PhD, Peiman Hematti, MD, Parameswaran Hari, MD MRCP, MS, Natalie Scott Callander, MD, Fotios Asimakopoulos, PhDMBBChir,

Blood (2017) 130 (Supplement 1): 1756.

https://doi.org/10.1182/blood.V130.Suppl_1.1756.1756

Published: 2017

Journal Articles

Initial Results of an Ex Vivo Microfluidic Cis -Coculture Csra to Predict Response for Myeloma Patients

Chorom Pak, PhD, Natalie S Callander, MD, Edmond WK Young, PhD, Benjamin Titz, PhD, KyungMann Kim, PhD, Kenny Chng, BA, Shigeki Miyamoto, PhD, David J Beebe, PhD

Blood (2014) 124 (21): 4706.

https://doi.org/10.1182/blood.V124.21.4706.4706

Published: 2014

Journal Articles

Microfluidic Platform Enabling Primary Multiple Myeloma Mono- and Cis -Co-Culture Analysis

Pak Chorom, BA, Edmond WK Young, PhD, Natalie Callander, MD, David J Beebe, PhD, Shigeki Miyamoto, PhD

Blood (2012) 120 (21): 1830.

https://doi.org/10.1182/blood.V120.21.1830.1830

Published: 2012

Journal Articles

Molecular Pathways That Determine the Activation State of Macrophages within the Myeloma Niche

Chelsea Hope, Ellen Hebron, Jaehyup Kim, MD, Jeff Jensen, Claire Flanagan, Neehar Bhatia, Catherine Leith, MBBChir, Ioanna Maroulakou, PhD, Constantine S. Mitsiades, MD, PhD, Shigeki Miyamoto, PhD, Natalie Callander, MD, Peiman Hematti, MD, Fotis Asimakopoulos, MBBChir, PhD

Blood (2012) 120 (21): 443.

https://doi.org/10.1182/blood.V120.21.443.443

Published: 2012

Journal Articles

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Andrew T Humbert, Rachel Cook, MS, MD, Thomas McFarland, Ronald Go, MD, Stephanie Markovina, MD, Shigeki Miyamoto, PhD, Eliot C. Williams, MD, PhD, Fotios Asimakopoulos, MBBChir, PhD, Jill Kolesar, PhD, Michael A. Thompson, MD, PhD, Kyungmann Kim, Natalie Callander, MD

Blood (2012) 120 (21): 5041.

https://doi.org/10.1182/blood.V120.21.5041.5041

Published: 2012

Journal Articles

The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).

Natalie Scott Callander, MD, Stephanie Markovina, BA, Mark B. Juckett, MD, Elizabeth Wagner, MA, Jill Kolesar, Walter Longo, Eliot C. Williams, MD, PhD, Kyungmann Kim, Jae Werndli, BSc, MSc, Shigeki Miyamoto, PhD

Blood (2009) 114 (22): 3885.

https://doi.org/10.1182/blood.V114.22.3885.3885

Published: 2009

Journal Articles

The Critical Role of Iκbα Dependent Nuclear Export of NF-κb in B-Cell Development.

David T Yang, MD, Shelly Wuerzberger-Davis, PhD, Yuhong Chen, PhD, Mei Yu, Hu Zeng, Paul Bates, PhD, Renren Wen, PhD, Demin Wang, PhD, Shigeki Miyamoto, PhD

Blood (2008) 112 (11): 1533.

https://doi.org/10.1182/blood.V112.11.1533.1533

Published: 2008

Journal Articles

Bortezomib Resistant Constitutive NF-κB Activation in Mantle Cell Lymphoma.

David T. Yang, MD, Ken H. Young, MD PhD, Brad S. Kahl, MD, Shigeki Miyamoto, PhD

Blood (2007) 110 (11): 3465.

https://doi.org/10.1182/blood.V110.11.3465.3465

Published: 2007

Journal Articles

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Martha Raschko, MD, Stephanie Markovina, Shigeki Miyamoto, PhD, Walter Longo, MD, Eliot Williams, MD, Thomas McFarland, MD, Jae Werndli, Elisabeth Wagner, Mark Juckett, MD, Natalie Callander, MD

Blood (2007) 110 (11): 1173.

https://doi.org/10.1182/blood.V110.11.1173.1173

Published: 2007

Journal Articles

Phase II Trial of Bortezomib Combined with Weekly Doxorubicin and Oral Dexamethasone for Relapsed or Refractory Multiple Myeloma (MM): Effect of NF-κB Activation on Response.

Natalie S. Callander, MD, Shigeki Miyamoto, PhD, Brad Kahl, MD, Stephanie Markovina, Martha Raschko, Jae Werndl, Catherine Leith, MBBDir, Alice McCoy, MD

Blood (2006) 108 (11): 3545.

https://doi.org/10.1182/blood.V108.11.3545.3545

Published: 2006

NARROW

Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination

Versican (VCAN) Proteolysis Predicts T-Cell Infiltration in Myeloma Bone Marrow Post- Autologous Stem Cell Transplant (ASCT)

Initial Results of an Ex Vivo Microfluidic Cis -Coculture Csra to Predict Response for Myeloma Patients

Microfluidic Platform Enabling Primary Multiple Myeloma Mono- and Cis -Co-Culture Analysis

Molecular Pathways That Determine the Activation State of Macrophages within the Myeloma Niche

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).

The Critical Role of Iκbα Dependent Nuclear Export of NF-κb in B-Cell Development.

Bortezomib Resistant Constitutive NF-κB Activation in Mantle Cell Lymphoma.

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Phase II Trial of Bortezomib Combined with Weekly Doxorubicin and Oral Dexamethasone for Relapsed or Refractory Multiple Myeloma (MM): Effect of NF-κB Activation on Response.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only